Compare BDJ & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BDJ | ABCL |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | N/A | 2020 |
| Metric | BDJ | ABCL |
|---|---|---|
| Price | $9.76 | $6.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.40 |
| AVG Volume (30 Days) | 422.9K | ★ 4.6M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 8.85% | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $75,128,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $21.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $8.42 | $2.75 |
| 52 Week High | $9.86 | $8.44 |
| Indicator | BDJ | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 59.82 | 56.61 |
| Support Level | $9.05 | $3.40 |
| Resistance Level | N/A | $6.79 |
| Average True Range (ATR) | 0.09 | 0.44 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 70.97 | 96.53 |
BlackRock Enhanced Equity Dividend Trust is a closed-end management investment company. Its primary investment objective is to provide current income and current gains, with a secondary objective of long-term capital appreciation. The trust seeks to achieve its investment objectives by investing in common stocks that pay dividends and have the potential for capital appreciation and by utilizing an option to enhance distributions to its shareholders.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.